APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR T-Cell-Based Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global CAR T-Cell-Based Drug Industry Growth and Trends Forecast to 2032

20 December 2025103 pages

Choose your research edition.

Industry ResearchCAR T-Cell-Based Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR T-Cell-Based Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CAR T-Cell-Based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR T-Cell-Based Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR T-Cell-Based Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

According to APO Research, the global CAR T-Cell-Based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CAR T-Cell-Based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the CAR T-Cell-Based Drug market include J & J, Novartis, Gilead Sciences, Bristol-Myers Squibb, Sorrento Therapeutics, Mustang Bio, JW Therapeutics, FOSUNKite and Celyad, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global CAR T-Cell-Based Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The CAR T-Cell-Based Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global CAR T-Cell-Based Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to CAR T-Cell-Based Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global CAR T-Cell-Based Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

CAR T-Cell-Based Drug Market by Company

J & J

Novartis

Gilead Sciences

Bristol-Myers Squibb

Sorrento Therapeutics

Mustang Bio

JW Therapeutics

FOSUNKite

Celyad

Cellectis

CARsgen Therapeutics

Bluebird Bio

Autolus Therapeutics

Allogene Therapeutics

CAR T-Cell-Based Drug Segment by Type

CD19-targeted

BCMA-targeted

CAR T-Cell-Based Drug Segment by Application

Lymphoma

Multiple Myeloma

CAR T-Cell-Based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell-Based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell-Based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell-Based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of CAR T-Cell-Based Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global CAR T-Cell-Based Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global CAR T-Cell-Based Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global CAR T-Cell-Based Drug Market Share by Region (2021-2026) Table 4. Global CAR T-Cell-Based Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global CAR T-Cell-Based Drug Market Share by Region (2027-2032) Table 6. Global CAR T-Cell-Based Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global CAR T-Cell-Based Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global CAR T-Cell-Based Drug Market Size Share by Type (2021-2026) Table 9. Global CAR T-Cell-Based Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global CAR T-Cell-Based Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America CAR T-Cell-Based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe CAR T-Cell-Based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific CAR T-Cell-Based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America CAR T-Cell-Based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa CAR T-Cell-Based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global CAR T-Cell-Based Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global CAR T-Cell-Based Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global CAR T-Cell-Based Drug Market Size Share by Application (2021-2026) Table 24. Global CAR T-Cell-Based Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global CAR T-Cell-Based Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America CAR T-Cell-Based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe CAR T-Cell-Based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific CAR T-Cell-Based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America CAR T-Cell-Based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa CAR T-Cell-Based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. CAR T-Cell-Based Drug Industry Trends Table 37. CAR T-Cell-Based Drug Industry Drivers Table 38. CAR T-Cell-Based Drug Industry Opportunities and Challenges Table 39. CAR T-Cell-Based Drug Industry Restraints Table 40. Global CAR T-Cell-Based Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global CAR T-Cell-Based Drug Revenue Market Share by Company (2021-2026) Table 42. Global CAR T-Cell-Based Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global CAR T-Cell-Based Drug Key Company Headquarters & Area Served Table 44. Global CAR T-Cell-Based Drug Company, Product Type & Application Table 45. Global CAR T-Cell-Based Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global CAR T-Cell-Based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. J & J Company Information Table 49. J & J Business Overview Table 50. J & J CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. J & J CAR T-Cell-Based Drug Product Portfolio Table 52. J & J Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis CAR T-Cell-Based Drug Product Portfolio Table 57. Novartis Recent Development Table 58. Gilead Sciences Company Information Table 59. Gilead Sciences Business Overview Table 60. Gilead Sciences CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Gilead Sciences CAR T-Cell-Based Drug Product Portfolio Table 62. Gilead Sciences Recent Development Table 63. Bristol-Myers Squibb Company Information Table 64. Bristol-Myers Squibb Business Overview Table 65. Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio Table 67. Bristol-Myers Squibb Recent Development Table 68. Sorrento Therapeutics Company Information Table 69. Sorrento Therapeutics Business Overview Table 70. Sorrento Therapeutics CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 72. Sorrento Therapeutics Recent Development Table 73. Mustang Bio Company Information Table 74. Mustang Bio Business Overview Table 75. Mustang Bio CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Mustang Bio CAR T-Cell-Based Drug Product Portfolio Table 77. Mustang Bio Recent Development Table 78. JW Therapeutics Company Information Table 79. JW Therapeutics Business Overview Table 80. JW Therapeutics CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. JW Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 82. JW Therapeutics Recent Development Table 83. FOSUNKite Company Information Table 84. FOSUNKite Business Overview Table 85. FOSUNKite CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. FOSUNKite CAR T-Cell-Based Drug Product Portfolio Table 87. FOSUNKite Recent Development Table 88. Celyad Company Information Table 89. Celyad Business Overview Table 90. Celyad CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Celyad CAR T-Cell-Based Drug Product Portfolio Table 92. Celyad Recent Development Table 93. Cellectis Company Information Table 94. Cellectis Business Overview Table 95. Cellectis CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Cellectis CAR T-Cell-Based Drug Product Portfolio Table 97. Cellectis Recent Development Table 98. CARsgen Therapeutics Company Information Table 99. CARsgen Therapeutics Business Overview Table 100. CARsgen Therapeutics CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 102. CARsgen Therapeutics Recent Development Table 103. Bluebird Bio Company Information Table 104. Bluebird Bio Business Overview Table 105. Bluebird Bio CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Bluebird Bio CAR T-Cell-Based Drug Product Portfolio Table 107. Bluebird Bio Recent Development Table 108. Autolus Therapeutics Company Information Table 109. Autolus Therapeutics Business Overview Table 110. Autolus Therapeutics CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 112. Autolus Therapeutics Recent Development Table 113. Allogene Therapeutics Company Information Table 114. Allogene Therapeutics Business Overview Table 115. Allogene Therapeutics CAR T-Cell-Based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 117. Allogene Therapeutics Recent Development Table 118. North America CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. North America CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 120. North America CAR T-Cell-Based Drug Market Share by Country (2021-2026) Table 121. North America CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. North America CAR T-Cell-Based Drug Market Share Forecast by Country (2027-2032) Table 123. Europe CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Europe CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 125. Europe CAR T-Cell-Based Drug Market Share by Country (2021-2026) Table 126. Europe CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Europe CAR T-Cell-Based Drug Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 130. Asia-Pacific CAR T-Cell-Based Drug Market Share by Country (2021-2026) Table 131. Asia-Pacific CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Asia-Pacific CAR T-Cell-Based Drug Market Share Forecast by Country (2027-2032) Table 133. Latin America CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America CAR T-Cell-Based Drug Market Share by Country (2021-2026) Table 136. Latin America CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America CAR T-Cell-Based Drug Market Share Forecast by Country (2027-2032) Table 138. Middle East & Africa CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021-2026) & (US$ Million) Table 140. Middle East & Africa CAR T-Cell-Based Drug Market Share by Country (2021-2026) Table 141. Middle East & Africa CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Middle East & Africa CAR T-Cell-Based Drug Market Share Forecast by Country (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. CAR T-Cell-Based Drug Product Image Figure 3. Global CAR T-Cell-Based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global CAR T-Cell-Based Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global CAR T-Cell-Based Drug Market Share by Region: 2025 VS 2032 Figure 6. Global CAR T-Cell-Based Drug Market Share by Region (2021-2032) Figure 7. North America CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. CD19-targeted Image Figure 13. Global CD19-targeted Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. BCMA-targeted Image Figure 15. Global BCMA-targeted Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global CAR T-Cell-Based Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global CAR T-Cell-Based Drug Market Share by Type 2025 VS 2032 Figure 18. North America CAR T-Cell-Based Drug Market Size Share by Type (2021-2032) Figure 19. Europe CAR T-Cell-Based Drug Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific CAR T-Cell-Based Drug Market Size Share by Type (2021-2032) Figure 21. Latin America CAR T-Cell-Based Drug Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa CAR T-Cell-Based Drug Market Size Share by Type (2021-2032) Figure 23. Lymphoma Image Figure 24. Global Lymphoma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Multiple Myeloma Image Figure 26. Global Multiple Myeloma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Global CAR T-Cell-Based Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global CAR T-Cell-Based Drug Market Share by Application 2025 VS 2032 Figure 29. North America CAR T-Cell-Based Drug Market Size Share by Application (2021-2032) Figure 30. Europe CAR T-Cell-Based Drug Market Size Share by Application (2021-2032) Figure 31. Asia-Pacific CAR T-Cell-Based Drug Market Size Share by Application (2021-2032) Figure 32. Latin America CAR T-Cell-Based Drug Market Size Share by Application (2021-2032) Figure 33. Middle East and Africa CAR T-Cell-Based Drug Market Size Share by Application (2021-2032) Figure 34. Global Top 5 and 10 CAR T-Cell-Based Drug Players Market Share by Revenue in 2025 Figure 35. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 36. North America CAR T-Cell-Based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. North America CAR T-Cell-Based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 38. North America CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 39. Europe CAR T-Cell-Based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 40. Europe CAR T-Cell-Based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 41. Europe CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 42. Asia-Pacific CAR T-Cell-Based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. Asia-Pacific CAR T-Cell-Based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. Asia-Pacific CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 45. Latin America CAR T-Cell-Based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Latin America CAR T-Cell-Based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Latin America CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 48. Middle East & Africa CAR T-Cell-Based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Middle East & Africa CAR T-Cell-Based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Middle East & Africa CAR T-Cell-Based Drug Market Share by Country (2021-2032) Figure 51. Years Considered Figure 52. Research Process Figure 53. Key Executives Interviewed

Scope & coverage.

Types
  • CD19-targeted
  • BCMA-targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • J & J
  • Novartis
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Sorrento Therapeutics
  • Mustang Bio
  • JW Therapeutics
  • FOSUNKite
  • Celyad
  • Cellectis
  • CARsgen Therapeutics
  • Bluebird Bio
  • Autolus Therapeutics
  • Allogene Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global CAR T-Cell-Based Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global CAR T-Cell-Based Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global CAR T-Cell-Based Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global CAR T-Cell-Based Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions CAR T-Cell-Based Drug Market Size (2021-2032)
  8. 1.5.1 North America CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa CAR T-Cell-Based Drug Market Size Growth Rate (2021-2032)
2 CAR T-Cell-Based Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 CD19-targeted
  3. 2.1.2 BCMA-targeted
  4. 2.2 Global CAR T-Cell-Based Drug Market Size by Type
  5. 2.2.1 Global CAR T-Cell-Based Drug Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global CAR T-Cell-Based Drug Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global CAR T-Cell-Based Drug Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global CAR T-Cell-Based Drug Market Size by Regions
  9. 2.3.1 North America CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa CAR T-Cell-Based Drug Market Size Breakdown by Type (2021-2026)
3 CAR T-Cell-Based Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Lymphoma
  3. 3.1.2 Multiple Myeloma
  4. 3.2 Global CAR T-Cell-Based Drug Market Size by Application
  5. 3.2.1 Global CAR T-Cell-Based Drug Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global CAR T-Cell-Based Drug Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global CAR T-Cell-Based Drug Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global CAR T-Cell-Based Drug Market Size by Regions
  9. 3.3.1 North America CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa CAR T-Cell-Based Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 CAR T-Cell-Based Drug Industry Trends
  2. 4.2 CAR T-Cell-Based Drug Industry Drivers
  3. 4.3 CAR T-Cell-Based Drug Industry Opportunities and Challenges
  4. 4.4 CAR T-Cell-Based Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by CAR T-Cell-Based Drug Revenue (2021-2026)
  2. 5.2 Global CAR T-Cell-Based Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global CAR T-Cell-Based Drug Key Company Headquarters & Area Served
  4. 5.4 Global CAR T-Cell-Based Drug Company, Product Type & Application
  5. 5.5 Global CAR T-Cell-Based Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global CAR T-Cell-Based Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 CAR T-Cell-Based Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 CAR T-Cell-Based Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 J & J
  2. 6.1.1 J & J Company Information
  3. 6.1.2 J & J Business Overview
  4. 6.1.3 J & J CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 J & J CAR T-Cell-Based Drug Product Portfolio
  6. 6.1.5 J & J Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis CAR T-Cell-Based Drug Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Gilead Sciences
  14. 6.3.1 Gilead Sciences Company Information
  15. 6.3.2 Gilead Sciences Business Overview
  16. 6.3.3 Gilead Sciences CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Gilead Sciences CAR T-Cell-Based Drug Product Portfolio
  18. 6.3.5 Gilead Sciences Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Sorrento Therapeutics
  26. 6.5.1 Sorrento Therapeutics Company Information
  27. 6.5.2 Sorrento Therapeutics Business Overview
  28. 6.5.3 Sorrento Therapeutics CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio
  30. 6.5.5 Sorrento Therapeutics Recent Developments
  31. 6.6 Mustang Bio
  32. 6.6.1 Mustang Bio Company Information
  33. 6.6.2 Mustang Bio Business Overview
  34. 6.6.3 Mustang Bio CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Mustang Bio CAR T-Cell-Based Drug Product Portfolio
  36. 6.6.5 Mustang Bio Recent Developments
  37. 6.7 JW Therapeutics
  38. 6.7.1 JW Therapeutics Company Information
  39. 6.7.2 JW Therapeutics Business Overview
  40. 6.7.3 JW Therapeutics CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 JW Therapeutics CAR T-Cell-Based Drug Product Portfolio
  42. 6.7.5 JW Therapeutics Recent Developments
  43. 6.8 FOSUNKite
  44. 6.8.1 FOSUNKite Company Information
  45. 6.8.2 FOSUNKite Business Overview
  46. 6.8.3 FOSUNKite CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 FOSUNKite CAR T-Cell-Based Drug Product Portfolio
  48. 6.8.5 FOSUNKite Recent Developments
  49. 6.9 Celyad
  50. 6.9.1 Celyad Company Information
  51. 6.9.2 Celyad Business Overview
  52. 6.9.3 Celyad CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Celyad CAR T-Cell-Based Drug Product Portfolio
  54. 6.9.5 Celyad Recent Developments
  55. 6.10 Cellectis
  56. 6.10.1 Cellectis Company Information
  57. 6.10.2 Cellectis Business Overview
  58. 6.10.3 Cellectis CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Cellectis CAR T-Cell-Based Drug Product Portfolio
  60. 6.10.5 Cellectis Recent Developments
  61. 6.11 CARsgen Therapeutics
  62. 6.11.1 CARsgen Therapeutics Company Information
  63. 6.11.2 CARsgen Therapeutics Business Overview
  64. 6.11.3 CARsgen Therapeutics CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio
  66. 6.11.5 CARsgen Therapeutics Recent Developments
  67. 6.12 Bluebird Bio
  68. 6.12.1 Bluebird Bio Company Information
  69. 6.12.2 Bluebird Bio Business Overview
  70. 6.12.3 Bluebird Bio CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Bluebird Bio CAR T-Cell-Based Drug Product Portfolio
  72. 6.12.5 Bluebird Bio Recent Developments
  73. 6.13 Autolus Therapeutics
  74. 6.13.1 Autolus Therapeutics Company Information
  75. 6.13.2 Autolus Therapeutics Business Overview
  76. 6.13.3 Autolus Therapeutics CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio
  78. 6.13.5 Autolus Therapeutics Recent Developments
  79. 6.14 Allogene Therapeutics
  80. 6.14.1 Allogene Therapeutics Company Information
  81. 6.14.2 Allogene Therapeutics Business Overview
  82. 6.14.3 Allogene Therapeutics CAR T-Cell-Based Drug Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio
  84. 6.14.5 Allogene Therapeutics Recent Developments
7 North America
  1. 7.1 North America CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  3. 7.3 North America CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  3. 8.3 Europe CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  3. 10.3 South America CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa CAR T-Cell-Based Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst